Coats Disease Clinical Trial
Official title:
Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease
This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography
Coats disease is an idiopathic retinal vascular disorder, occurs in young males, and is
characterized by retinal telangiactasias, numerous yellowish exudates in the subretinal
space, macular edema, hemorrhages and, in advanced end-stage, by exudative retinal
detachment.
Ranibizumab is a vascular endothelial growth factor antagonist represent an efficacy
treatment acting on vascular hyperpermeability. The optical coherence tomography and optical
coherence tomography angiography represent novel and non-invasive diagnostic techniques that
allow a detailed analysis of retinal and vascular features. The study evaluates the changes
in optical coherence tomography and optical coherence tomography angiography parameters at
baseline and after three monthly injections of Ranibizumab in Coats disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04089995 -
Coats Plus Syndrome and LCC Syndrome: Series of 10 Pediatric Cases. Review of Literature and Natural History
|
||
| Suspended |
NCT03940690 -
Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
|
Phase 3 |